Affordable Access

deepdyve-link
Publisher Website

Transmitted HIV-1 Drug Resistance in a Treatment-Naive Cohort of Recently Infected Individuals from Chennai, India.

Authors
  • Nesakumar, Manohar1
  • Haribabu, Hemalatha1
  • Cheedarla, Narayanaiah1
  • Karunaianantham, Ramesh1
  • Kailasam, Nandagopal2
  • Sathyamurthi, Pattabiraman1
  • Selvachithiram, Murugesan1
  • Tripathy, Srikanth Prasad1
  • Hanna, Luke Elizabeth1
  • 1 1Department of HIV/AIDS, National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India. , (India)
  • 2 2ART Centre, Kilpauk Medical College and Hospital, Chennai, India. , (India)
Type
Published Article
Journal
AIDS Research and Human Retroviruses
Publisher
Mary Ann Liebert
Publication Date
Aug 01, 2019
Volume
35
Issue
8
Pages
775–779
Identifiers
DOI: 10.1089/AID.2019.0022
PMID: 31001987
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

A cross-sectional study was undertaken to examine the prevalence and pattern of HIV drug resistance mutations (DRMs) among recently HIV-1-infected and antiretroviral therapy (ART)-naive individuals from Chennai, South India. The HIV-1 pol gene encompassing the protease and reverse transcriptase (RT) regions were analyzed from 53 ART-naive HIV-1-infected individuals using an in-house method for identifying DRMs by genotyping. The overall prevalence of transmitted drug resistance (TDR) was found to be 11.3% (6/53), which is categorized as moderate level (5.0%-15.0%) of TDR according to the World Health Organization (WHO) survey guidelines. Surveillance drug resistance mutations to non-nucleoside reverse transcriptase inhibitors (NNRTI) were observed in 8.3% (n = 4) of the 48 RT sequences analyzed. No major DRMs related to the protease and nucleoside reverse transcriptase inhibitor (NRTIs) class of drugs were identified.

Report this publication

Statistics

Seen <100 times